𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography

✍ Scribed by Erkki Tupala; Håkan Hall; Kim Bergström; Tuija Mantere; Pirkko Räsänen; Terttu Särkioja; Jari Tiihonen


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
280 KB
Volume
20
Category
Article
ISSN
1065-9471

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Increasing evidence implies the involvement of the dopamine (DA) system in the pathogenesis of alcoholism. We measured striatal DA D~2~ receptors in Cloninger type 1 and 2 alcoholics by using [^125^I]epidepride in human postmortem whole hemispheric autoradiography (WHA), which provides high‐resolution images corresponding to positron emission tomographic (PET) studies. We also evaluated the correlation between transporter and receptor DA binding site densities and putative correlation of [^125^I]epidepride binding between the dorsal striatum and nucleus accumbens. In the type 1 alcoholics, the DA D~2~ receptor density was 21.4–32.6% lower in all dorsal striatal structures (caudate, putamen, globus pallidus) when compared with the controls. Type 2 alcoholics had 19.6–21.4% lower binding in other dorsal striatal structures, except medial globus pallidus, where they were not significantly different from controls. The density of DA D~2~ receptors and DAT had a significant positive correlation only in the putamen of type 1 alcoholics. The binding of [^125^I]epidepride showed also consistent and statistically significant positive correlation between nucleus accumbens and all dorsal striatal areas in type 1 alcoholics but not in the controls. In the type 2 alcoholics, the correlation was weaker than that observed in the type 1 alcoholics, and no correlation was observed between nucleus accumbens and globus pallidus. Our results show that these two subgroups of alcoholics have stark differences in their DA D~2~ receptor binding characteristics. Type 2 alcoholics may have selective deficiency in the dorsal striatum, whereas in limbic structures they may not differ significantly from controls. Moreover, WHA provides a useful tool for detailed mapping of neuronal receptors in healthy as well as diseased brain, and can also be used in radioligand development for PET. Hum. Brain Mapp. 20:91–102, 2003. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


L-dopa–responsive Parkinson's syndrome i
✍ Andrew H. Evans; Durval C. Costa; Sveto Gacinovic; Regina Katzenschlager; John D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## Abstract Reports of parkinsonism in phenylketonuria are exceedingly rare. We report on a patient who had received a delayed diagnosis of phenylketonuria as an infant and subsequently developed levodopa‐responsive parkinsonism at the age of 33. Single‐photon emission computed tomography (SPECT) u

Electrostatic medium effects and formal
✍ Juan Sebastián Gómez-Jeria; Mario Ojeda-Vergara 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

The binding of apomorphines AM to D and D dopamine receptors is analyzed 1 2 through a formal quantum structure᎐activity relationship method. The calculations were carried out at the CNDOr2 level of the molecular orbital theory with a continuum representation of environmental effects. The results sh

Time course of changes in striatal dopam
✍ Sylvie Chalon; Patrick Emond; Sylvie Bodard; Marie-Paule Vilar; Cynthia Thiercel 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

The time course of the loss in presynaptic dopamine transporters (DAT) and of the increase in postsynaptic dopamine D2 receptors (D2R) was studied in a rat model of Parkinson's disease. For this, in vitro autoradiographic experiments were performed in the striatum using (E)-N-(3-iodoprop-2-enyl)-2be

Association study of dopamine D2, D3, D4
✍ Sebastian Paus; Gert Seeger; Hans M. Brecht; Jürgen Köster; Mahha El-Faddagh; Ma 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 1 views

Sleep attacks are a common yet only recently recognized phenomenon in patients with Parkinson's disease (PD). Initially reported to occur only with particular dopamine agonists, sleep attacks have been observed with all dopaminergic drugs. [1][2][3] In the majority of affected patients, sleep attack